Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Modine Manufacturing Company (MOD) vs Zoetis Inc (ZTS) Price & Performance

Modine Manufacturing CompanyTrade
Zoetis IncTrade

Price performance (Past 24H)

Key statistics

Modine Manufacturing Company vs Zoetis Inc — how do they compare? Modine Manufacturing Company trades at $184.98 (market cap $9.66B), while Zoetis Inc trades at $73.02 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 3.1× Modine Manufacturing Company's market cap, and Zoetis Inc pays a 2.9% dividend while Modine Manufacturing Company pays none. Which is the better fit depends on your goals — on Pluang, investors hold Modine Manufacturing Company for 33 Days and Zoetis Inc for 70 Days on average.

MODZTS
Market Cap
$9.66B$30.20B
Volume
1,331,9466,175,327
Sector
IndustrialsHealth
52-Week High
$283.95$147.53
52-Week Low
$110.73$69.09
Typical Hold Time
33 Days70 Days
Enterprise Value
$10.09B$37.76B
Dividend Yield
—2.9%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Modine Manufacturing Company

Modine Manufacturing (MOD) trades at $189.44, down 0.25% on the day, with a neutral technical signal. The stock shows strong fundamental performance, beating earnings estimates for three consecutive quarters, and benefits from a bullish analyst consensus with a $331.25 price target. Recent corporate actions include the completion of a $946 million spin-off of its Performance Technologies unit, potentially streamlining operations for future growth.

The outlook remains positive given earnings momentum and strategic focus on thermal management solutions, but risks include a high P/E ratio of 70.69 and potential integration challenges post-spin-off. Revenue growth to $3.4B in 2026, though with a declining net margin, suggests scaling operations may pressure profitability near-term.

Zoetis Inc

Zoetis (ZTS) trades at $71.55, showing modest daily gains of 0.32% amid a challenging market environment. The stock faces bearish technical signals with mixed quarterly earnings performance - beating expectations in Q2 2026 but missing in Q1. Strong fundamentals persist with 71.67% gross margins and 27.69% net income margins, though recent headwinds include U.S. companion animal market weakness and increased competition in key therapeutic areas. The company maintains robust cash flow generation with $2.9 billion from operations in 2025.

Despite near-term pressures, ZTS presents value opportunity with attractive valuation at 11.67 P/E ratio and consensus price target of $87.33 suggesting 22% upside. Risks include ongoing competitive pressures and U.S. market softness, but industry-leading profitability and international growth provide stability. Analyst sentiment remains positive with no sell ratings among 32 covering firms, though technical indicators suggest cautious near-term positioning.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

MOD
100% Buy0% Sell
Avg holding period · 33 Days
ZTS

No sentiment data available yet.

Top news

Latest headlines on both assets

About Modine Manufacturing Company

Modine Manufacturing Company is a global leader in thermal management technology and solutions. The company engineers, manufactures, and markets heat transfer products for a wide range of applications across the automotive, commercial, industrial, and HVAC (heating, ventilation, and air conditioning) markets. Modine's products include engine cooling systems, heat exchangers, and ventilation systems, providing critical thermal solutions for vehicles, data centers, and various equipment worldwide.

Read more on MOD →

About Zoetis Inc

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Read more on ZTS →